Tags : Update

Denali and Sanofi Provide Update on its RIPK1 Program

Shots: Denali reported the results of P-Ib studies of DNL747 in AD and ALS and provides an update on its broad RIPK1 program including DNL788 and DNL758. The P-Ib studies has met its safety endpoints in patients with ALS and AD, further dose escalation to achieve higher levels of target inhibition may be limited by […]Read More

Formycon To Update on its Biosimilar Programs

Formycon signs an agreement with Bioeq AG and manufacturing partner for resubmission of BLA for FYB201 project (biosimilar, ranibizumab). Bioeq AG is in talks with the US FDA for resubmission supporting manufacturing data in the H2’20 In Oct 2019, Formycon’s FYB202 (biosimilar, ustekinumab) has completed its P-I trial with its initiation of P-III trial in […]Read More

Xbrane Biopharma Reports Update on the Ongoing P-III Xplore Study

Shots: Xlucane is still on track towards regulatory approval ahead of Lucentis’ patent expiration in EU July 2022. Despite the COVID-19, Xplore will continue the recruitment of new patients and treatment for patients currently in the study Xbrane will ensure the safety participants in the P-III study as well as the integrity of study data […]Read More

Amgen Provides Update on its Clinical Activities and Medicine Supply

Shots: Amgen anticipates no disruption in its supply of medicines for patients across the globe due to COVID-19 and is expected to have no shortage of its therapies The company has temporarily paused the enrollment/screening in clinical studies to ensure the safety of subjects or integrity of data during a pandemic Amgen reported that P-II […]Read More

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in

Shots: The P-III CheckMate -915 study involves assessing of Opdivo (240mg, IV, q2w) in combination with Yervoy (1 mg/kg, q6w) vs Opdivo (480mg, q4w) as monothx. as the adjuvant therapy in 1,943 patients who have had complete surgical removal of stage IIIb/c/d or stage IV melanoma The P-III CheckMate -915 study did not meet its […]Read More

Celgene Reports Update on its Collaboration with Jounce Therapeutics

Shots: Jounce to receive $50M up front, $180M as development & regulatory milestones, $300M as commercial milestones, royalties on global sales and will retain WW rights to its pipeline including vopratelimab, JTX-4014 and all discovery programs Celgene to get WW rights to develop & commercialize Jounce’s JTX-8064, an anti-leukocyte immunoglobulin like receptor B2 (LILRB2) Ab, […]Read More